$ALHC earnings report

Alignment Healthcare Reports Third Quarter 2026 Results, Updates Full-Year Outlook. AlphAI read Alignment Healthcare's Third Quarter 2026 filing as mixed. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readALHC · Third Quarter 2026 · ended Sept. 30, 2026

Alignment Healthcare Reports Third Quarter 2026 Results, Updates Full-Year Outlook

→Mixed quarter

Revenue and membership grew 36.7% and 31.2% year-over-year, respectively, but higher medical costs drove a 32.8% decline in adjusted EBITDA, a net loss of $8.1 million, and lower full-year adjusted gross profit and adjusted EBITDA guidance.

Revenue
$1.36B
up 36.7% year-over-year y/y
EPS · GAAP
(0.04)
Three Months Ending December 31, 2026 and Twelve Months Ending December 31, 2026 outlook
$1,316 for three months ending December 31, 2026; $5,245 for twelve months ending December 31, 2026

Actuals vs. the company’s prior outlook

from its previous release
MetricGuidedReportedVerdict
Revenue, Q3$1,300 to $1,320$ 1,358,290 (in thousands)above
Adjusted gross profit, Q3$148 to $158$ 142,205 (in thousands)below

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Health plan membership at end of quarterotherapproximately 301,200–up 31.2% year-over-year
Total revenues, three months ended September 30, 2026GAAP$1.36B–up 36.7% year-over-year
Earned premiums, three months ended September 30, 2026GAAP$1.35B––
Other revenue, three months ended September 30, 2026GAAP$10.03M––
Medical expenses, three months ended September 30, 2026GAAP$1.22B––
Medical benefits ratio, three months ended September 30, 2026non-GAAP89.5%–an increase of approximately 240 basis points year-over-year
Selling, general, and administrative expenses, three months ended September 30, 2026GAAP$136.4M––
Depreciation and amortization, three months ended September 30, 2026GAAP$8.11M––
Total expenses, three months ended September 30, 2026GAAP$1.36B––
Loss from operations, three months ended September 30, 2026GAAP−$3.79M––
Adjusted gross profit, three months ended September 30, 2026non-GAAP$142.2M–up 11.6% year-over-year
Interest expense, three months ended September 30, 2026GAAP$4.28M––
Income (loss) before income taxes, three months ended September 30, 2026GAAP−$8.07M––
Provision (benefit) for income taxes, three months ended September 30, 2026GAAP−$22K––
Net income (loss), three months ended September 30, 2026GAAP−$8.05M––
Net income (loss) attributable to Alignment Healthcare, Inc., three months ended September 30, 2026GAAP−$8.05M––
Basic net income (loss) per share attributable to Alignment Healthcare, Inc., three months ended September 30, 2026GAAP(0.04)––
Diluted net income (loss) per share attributable to Alignment Healthcare, Inc., three months ended September 30, 2026GAAP(0.04)––
Adjusted EBITDA, three months ended September 30, 2026non-GAAP$21.81M–declined 32.8% year-over-year
Adjusted EBITDA margin, three months ended September 30, 2026non-GAAP1.6%––
Total revenues, nine months ended September 30, 2026GAAP$3.93B––
Earned premiums, nine months ended September 30, 2026GAAP$3.90B––
Other revenue, nine months ended September 30, 2026GAAP$27.67M––
Medical expenses, nine months ended September 30, 2026GAAP$3.46B––
Selling, general, and administrative expenses, nine months ended September 30, 2026GAAP$388.5M––
Depreciation and amortization, nine months ended September 30, 2026GAAP$23.80M––
Total expenses, nine months ended September 30, 2026GAAP$3.88B––
Income from operations, nine months ended September 30, 2026GAAP$53.81M––
Adjusted gross profit, nine months ended September 30, 2026non-GAAP$471.0M––
Net income, nine months ended September 30, 2026GAAP$39.92M––
Net income attributable to Alignment Healthcare, Inc., nine months ended September 30, 2026GAAP$39.92M––
Basic net income per share attributable to Alignment Healthcare, Inc., nine months ended September 30, 2026GAAP0.19––
Diluted net income per share attributable to Alignment Healthcare, Inc., nine months ended September 30, 2026GAAP0.19––
Adjusted EBITDA, nine months ended September 30, 2026non-GAAP$127.8M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Three Months Ending December 31, 2026 and Twelve Months Ending December 31, 2026 outlook

  • Revenue$1,316 for three months ending December 31, 2026; $5,245 for twelve months ending December 31, 2026
  • NoteHealth Plan Membership: no less than 305,000 for three months ending December 31, 2026; no less than 305,000 for twelve months ending December 31, 2026
  • NoteAdjusted Gross Profit: $104 for three months ending December 31, 2026; $575 for twelve months ending December 31, 2026
  • NoteAdjusted EBITDA: $(28) for three months ending December 31, 2026; $100 for twelve months ending December 31, 2026

What drove it

  • Health plan membership was approximately 301,200, up 31.2% year-over-year.
  • Total revenue was $1,358.3 million, up 36.7% year-over-year.
  • Full-year health plan membership and revenue guidance was raised to reflect continued sales momentum.
  • Medical benefits ratio reflected previously expected changes in Part D seasonality and timing of clinical investments.

Concerns

  • Medical trends ran higher than expected.
  • The medical benefits ratio was 89.5%, an increase of approximately 240 basis points year-over-year.
  • The company cited higher costs from elevated appeals and disputes and increased costs within catastrophic cases and skilled nursing categories.
  • Full-year adjusted gross profit and adjusted EBITDA guidance was lowered to reflect higher medical costs experienced during the third quarter.
  • The third quarter recorded a loss from operations of $3.8 million and net loss of $8.1 million.

What to watch

  • Execution against actions underway, which revised guidance does not assume will provide any benefit.
  • Fourth-quarter medical-cost trends, including appeals and disputes, catastrophic cases, and skilled nursing categories.
  • Health plan membership against guidance of no less than 305,000.
  • Fourth-quarter adjusted gross profit guidance of $104 and adjusted EBITDA guidance of $(28).
  • Full-year adjusted gross profit guidance of $575 and adjusted EBITDA guidance of $100.

Balance sheet and cash flow

  • Cash and cash equivalents as of September 30, 2026: $ 727,694; December 31, 2025: $ 575,817
  • Investments - current as of September 30, 2026: 15,260; December 31, 2025: 28,413
  • Total assets as of September 30, 2026: $ 1,296,863; December 31, 2025: $ 1,065,786
  • Medical expenses payable as of September 30, 2026: $ 621,746; December 31, 2025: $ 474,569
  • Long-term debt, net of debt issuance costs, as of September 30, 2026: 324,497; December 31, 2025: 323,176
  • Total liabilities as of September 30, 2026: 1,019,751; December 31, 2025: 886,509
  • Total stockholders' equity as of September 30, 2026: 277,112; December 31, 2025: 179,277
  • Net cash provided by operating activities, nine months ended September 30, 2026: 158,395; 2025: 190,302
  • Acquisition of property and equipment, nine months ended September 30, 2026: (25,952); 2025: (21,752)
  • Net cash used in investing activities, nine months ended September 30, 2026: (12,327); 2025: (7,811)
  • Net cash provided by financing activities, nine months ended September 30, 2026: 5,834; 2025: 2,745
  • Net increase in cash, nine months ended September 30, 2026: 151,902; 2025: 185,236
  • Cash, cash equivalents and restricted cash at end of period, September 30, 2026: $ 729,839; September 30, 2025: $ 620,178

Analysis

Alignment reported third-quarter total revenue of $1,358.3 million, up 36.7% year-over-year, while health plan membership reached approximately 301,200, up 31.2% year-over-year. The company characterized the membership and revenue results as evidence of continued demand, and raised full-year health plan membership and revenue guidance to reflect continued sales momentum.

Profitability lagged the top-line expansion. Adjusted gross profit increased 11.6% year-over-year to $142.2 million, while the medical benefits ratio was 89.5%, an increase of approximately 240 basis points year-over-year. Management attributed the result to expected Part D seasonality and clinical-investment timing, alongside higher costs from elevated appeals and disputes and increased catastrophic-case and skilled-nursing costs.

The cost pressure moved quarterly GAAP results into loss territory. Loss from operations was $3.8 million compared with income from operations of $7.7 million in the prior-year quarter, and net loss was $8.1 million compared with net income of $3.7 million. Adjusted EBITDA declined 32.8% year-over-year to $21.8 million, with an adjusted EBITDA margin of 1.6%.

The balance sheet showed $727.7 million of cash and cash equivalents and $324.5 million of long-term debt, net of debt issuance costs, at September 30, 2026. Net cash provided by operating activities for the nine months ended September 30, 2026 was $158.4 million, compared with $190.3 million in the prior-year period. The release reported no capital-return activity.

For the fourth quarter, the company guided to revenue of $1,316, adjusted gross profit of $104, and adjusted EBITDA of $(28). Full-year guidance calls for revenue of $5,245, adjusted gross profit of $575, and adjusted EBITDA of $100, with health plan membership of no less than 305,000. The company lowered its adjusted gross profit and adjusted EBITDA outlook based on third-quarter medical costs and stated that revised guidance assumes no benefit from actions underway.

Management, verbatim

Our third-quarter membership and revenue growth demonstrate continued demand for Alignment’s products and services, while medical trends ran higher than expected.

John Kao, chairman and CEO

We are taking a prudent approach to the fourth quarter and lowering our outlook based on current headwinds.

John Kao, chairman and CEO

Our revised guidance does not assume any benefit from the actions underway.

John Kao, chairman and CEO

Not in the filing

stated, not guessed
  • GAAP gross margin was not reported.
  • Prior-quarter comparisons were not reported for the disclosed operating metrics.
  • No reportable revenue segments or segment-level results were provided.
  • Free cash flow was not reported.
  • Share repurchases, dividends, and other capital-return activity were not reported.
  • Fourth-quarter and full-year guidance for operating expenses and tax rate was not reported.
  • GAAP EPS guidance was not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readALHC · Second Quarter 2026 · ended June 30, 2026

Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics

✓Strong quarter

Total revenue grew 31.6% year-over-year, health plan membership grew 31.5%, adjusted gross profit grew 35.3%, adjusted EBITDA grew 48.4%, and the company raised the midpoint of all full-year guidance metrics.

Revenue
$1.34B
31.6% y/y
Three Months Ending September 30, 2026 and Twelve Months Ending December 31, 2026 outlook
$1,300 to $1,320; $5,195 to $5,225

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Health plan membership at the end of the quarterotherapproximately 294,100 members–31.5%
Total revenuesGAAP$1.34B–31.6%
Earned premiumsGAAP$1.33B––
Other revenueGAAP$9.01M––
Medical expensesGAAP$1.15B––
Income from operationsGAAP$42.1M––
Net incomeGAAP$36.56M––
Adjusted gross profitnon-GAAP$182.9M–35.3%
Medical benefits ratio based on adjusted gross profitnon-GAAP86.3%–an improvement of approximately 40 basis points
Adjusted EBITDAnon-GAAP$68.14M–48.4%
Adjusted EBITDA marginnon-GAAP5.1%––
Depreciation and amortizationGAAP$7.86M––
Interest expenseGAAP$4.28M––
Income tax expenseGAAP$1.27M––
Equity-based compensationGAAP$18.17M––
Litigation costsGAAP$14K––
Gain on sale of property and equipmentGAAP−$1K––
Six-month total revenuesGAAP$2.57B––
Six-month earned premiumsGAAP$2.55B––
Six-month other revenueGAAP$17.64M––
Six-month medical expensesGAAP$2.25B––
Six-month income from operationsGAAP$57.60M––
Six-month net incomeGAAP$47.98M––
Six-month adjusted gross profitnon-GAAP$328.8M––
Six-month adjusted EBITDAnon-GAAP$106.0M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Three Months Ending September 30, 2026 and Twelve Months Ending December 31, 2026 outlook

  • Revenue$1,300 to $1,320; $5,195 to $5,225
  • NoteHealth Plan Membership: 295,500 to 297,500; 298,000 to 301,000
  • NoteAdjusted Gross Profit: $148 to $158; $630 to $650
  • NoteAdjusted EBITDA: $20 to $30; $145 to $163

What drove it

  • Health plan membership at the end of the quarter was approximately 294,100, up 31.5% year-over-year.
  • Total revenue was $1,335.6 million, up 31.6% year-over-year.
  • Adjusted gross profit was $182.9 million, up 35.3% year-over-year.
  • Medical benefits ratio based on adjusted gross profit was 86.3%, an improvement of approximately 40 basis points year-over-year.
  • The company cited investments across its clinical model, AI-enabled capabilities and operational infrastructure.

Concerns

  • The company identified potential federal reductions in MA funding, changes in applicable laws and regulations, and risks related to indebtedness among risks that could cause results to differ materially from its outlook.
  • Other disclosed risks include the ability to attract new members and enter new markets, maintain plan ratings, maintain provider relationships, manage labor costs, and address litigation or a security incident.
  • Third-quarter adjusted gross profit guidance of $148 to $158 and adjusted EBITDA guidance of $20 to $30 are below the second-quarter reported amounts of $182.9 million and $68.1 million, respectively.

What to watch

  • Health plan membership against third-quarter guidance of 295,500 to 297,500 and full-year guidance of 298,000 to 301,000.
  • Revenue against third-quarter guidance of $1,300 to $1,320 and full-year guidance of $5,195 to $5,225.
  • Adjusted gross profit against third-quarter guidance of $148 to $158 and full-year guidance of $630 to $650.
  • Adjusted EBITDA against third-quarter guidance of $20 to $30 and full-year guidance of $145 to $163.
  • Medical benefits ratio based on adjusted gross profit following the reported approximately 40 basis point year-over-year improvement.

Balance sheet and cash flow

  • Cash and cash equivalents: $ 693,453 (in thousands) as of June 30, 2026; $ 575,817 (in thousands) as of December 31, 2025.
  • Investments - current: $ 8,258 (in thousands) as of June 30, 2026; $ 28,413 (in thousands) as of December 31, 2025.
  • Total current assets: $ 1,160,449 (in thousands) as of June 30, 2026; $ 951,577 (in thousands) as of December 31, 2025.
  • Total assets: $ 1,279,038 (in thousands) as of June 30, 2026; $ 1,065,786 (in thousands) as of December 31, 2025.
  • Medical expenses payable: $ 612,748 (in thousands) as of June 30, 2026; $ 474,569 (in thousands) as of December 31, 2025.
  • Long-term debt, net of debt issuance costs: $ 324,056 (in thousands) as of June 30, 2026; $ 323,176 (in thousands) as of December 31, 2025.
  • Total liabilities: $ 1,013,907 (in thousands) as of June 30, 2026; $ 886,509 (in thousands) as of December 31, 2025.
  • Total stockholders' equity: $ 265,131 (in thousands) as of June 30, 2026; $ 179,277 (in thousands) as of December 31, 2025.

Analysis

Alignment Healthcare reported a strong second quarter, led by 31.5% year-over-year health plan membership growth to approximately 294,100 members and 31.6% revenue growth to $1,335.6 million. Earned premiums were $1,326,625 (in thousands), while other revenue was $9,008 (in thousands). The six-month revenue total was $2,570,830 (in thousands), compared with $1,942,220 (in thousands) in the prior-year period.

Profitability improved faster than revenue on the measures highlighted by the company. Adjusted gross profit increased 35.3% year-over-year to $182.9 million, and the medical benefits ratio based on adjusted gross profit was 86.3%, an improvement of approximately 40 basis points year-over-year. Income from operations was $42.1 million, compared with $22.7 million in the prior-year quarter, while net income was $36.6 million, compared with $15.7 million.

Adjusted EBITDA rose 48.4% year-over-year to $68.1 million and represented a 5.1% adjusted EBITDA margin. The adjusted EBITDA reconciliation includes $18.2 million of equity-based compensation, $7.9 million of depreciation and amortization, $4.3 million of interest expense, and $1.3 million of income tax expense. Management attributed the results to its clinical model, AI-enabled capabilities and operational infrastructure.

The balance sheet showed $693.5 million of cash and cash equivalents as of June 30, 2026, compared with $575.8 million as of December 31, 2025. Long-term debt, net of debt issuance costs, was $324.1 million, compared with $323.2 million at year-end. Medical expenses payable were $612.7 million, compared with $474.6 million at December 31, 2025.

Management raised the midpoint of all full-year guidance metrics. The company guided third-quarter revenue to $1,300 to $1,320 and full-year revenue to $5,195 to $5,225. Full-year adjusted gross profit guidance is $630 to $650 and adjusted EBITDA guidance is $145 to $163. The principal reported operating indicators to monitor are membership conversion into the guided range, the medical benefits ratio, and execution against the lower third-quarter adjusted gross profit and adjusted EBITDA ranges relative to second-quarter results.

Management, verbatim

Our second quarter results underscore the strength of our purpose-built Medicare Advantage platform and place us in a strong position to deliver upon our full-year objectives.

John Kao, chairman and CEO

We are continuing to realize the benefits of ongoing investments we have made across our clinical model, AI-enabled capabilities and operational infrastructure.

John Kao, chairman and CEO

These financial results are a reflection of how we are delivering for our seniors and demonstrate that better outcomes, stronger member experiences and sustainable profitable growth can all go hand in hand.

John Kao, chairman and CEO

Not in the filing

stated, not guessed
  • Prior outlook was not provided; comparison of actual results with prior guidance is unavailable.
  • GAAP gross margin was not reported in the provided filing text.
  • GAAP and non-GAAP diluted EPS were not available in the provided filing text, which truncates during the statements of operations.
  • Operating cash flow and free cash flow were not reported in the provided filing text.
  • Share repurchases and dividend information were not reported in the provided filing text.
  • Segment revenue disclosures were not reported in the provided filing text.
  • Third-quarter and full-year guidance for operating expenses and tax rate were not reported.
  • Prior-quarter comparisons for reported quarterly operating metrics were not reported.
  • The condensed consolidated statements of operations were truncated after the medical expenses line in the provided filing text; remaining GAAP expense, income, and per-share line items are unavailable.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about ALHC earnings dates

When is Alignment Healthcare's next earnings date?
AlphAI has no date for ALHC yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.